Related Experiment Video
Updated: Sep 17, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Fausto Petrelli1, Elena Verri2, Antonio Ghidini3
1Oncology Unit, ASST Bergamo ovest, Treviglio (BG), Italy.
Importance:
Non-clear cell renal cell carcinomas (nccRCCs) present considerable challenges owing to their heterogeneity and limited clinical trial representation. Understanding the benefits of combining immunotherapy and targeted therapy for these subtypes is crucial for improving patient outcomes.
Objective:
To evaluate the efficacy of various first-line immunotherapy combinations and targeted therapy in treating metastatic nccRCC.
Data Sources:
A systematic literature search was conducted across PubMed, Embase, and Cochrane Library databases from inception until December 31, 2024, using relevant keywords and medical subject headings terms.
Study Selection:
Studies were included if they involved patients with nccRCC, reported on immune checkpoint inhibitor (ICI)-based therapies, and provided data on objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and disease control rate (DCR).
Data Extraction And Synthesis:
Two independent reviewers extracted data, with discrepancies resolved by a third expert. Observational study quality was assessed using the Newcastle-Ottawa Scale. A random-effects meta-analysis was performed, and heterogeneity was evaluated using the I2 statistic.
Main Outcome And Measures:
The primary outcomes of interest were ORR, PFS, OS, and DCR.
Results:
The analysis included 23 studies encompassing various subtypes of nccRCC. Pooled results indicated an ORR of 26.6% and a DCR of 57.8% for nccRCC treatments. Median PFS was 6.59 months, and the median OS was 21.11 months. ICIs demonstrated significant efficacy in nccRCC, exhibiting marked clinical activity across different subtypes. Although monotherapy with ICIs showed effectiveness, combination therapies yielded superior clinical outcomes.
Conclusions And Relevance:
This systematic review and meta-analysis found that ICIs, particularly when combined with targeted therapies, showed promising efficacy in treating metastatic nccRCC. These findings support their integration into treatment guidelines and emphasize the importance of personalized treatment strategies. Future research should focus on long-term outcomes, safety profiles, and the identification of biomarkers to optimize patient selection and improve outcomes.
Insights
Combining immunotherapy and targeted therapy shows promise for non-clear cell renal cell carcinoma (nccRCC). These treatments improve outcomes for metastatic nccRCC patients, supporting their use in clinical guidelines.
Area of Science:
- Oncology
- Medical Research
Background:
- Non-clear cell renal cell carcinomas (nccRCCs) are challenging due to heterogeneity and limited clinical trial data.
- Understanding treatment benefits for nccRCC subtypes is vital for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of first-line immunotherapy combinations and targeted therapy for metastatic nccRCC.
- To synthesize current evidence on treatment outcomes for nccRCC.
Main Methods:
- Systematic literature search of PubMed, Embase, and Cochrane Library databases up to December 31, 2024.
- Inclusion of studies on nccRCC treated with immune checkpoint inhibitors (ICIs), reporting objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and disease control rate (DCR).
- Random-effects meta-analysis of 23 studies, with data extraction and quality assessment by independent reviewers.
Main Results:
- Pooled analysis of 23 studies in nccRCC showed an ORR of 26.6% and DCR of 57.8%.
- Median PFS was 6.59 months and median OS was 21.11 months.
- Immune checkpoint inhibitors (ICIs) demonstrated significant efficacy, with combination therapies outperforming monotherapy.
Conclusions:
- Immune checkpoint inhibitors (ICIs) combined with targeted therapies show promising efficacy in metastatic nccRCC.
- Findings support integrating these combinations into treatment guidelines for nccRCC.
- Further research on long-term outcomes, safety, and biomarkers is recommended for personalized nccRCC treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Kidney Transplant II: Surgical Procedure
02:56Treatment Resistant Cancers
01:28Chronic Kidney Disease III: Interprofessional Care
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy